**DOCKET NO.:** CELL-0145 **Application No.:** 09/964,161 **Office Action Dated:** 04/23/2003

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

## 1. (currently amended)

A compound of formula (1):

$$R^{1}(Alk^{1})_{r}(L^{1})_{s}$$

$$(Alk^{2})_{m}$$

$$C(R^{2})$$

$$R^{b}$$

$$R^{b}$$

$$R^{b}$$

$$C(R^{2})$$

$$R^{3})COHeff$$

wherein:

R is a carboxylic acid group or a an ester or amide derivative thereof;

R<sup>1</sup> is a hydrogen atom or a hydroxyl, straight or branched alkoxy, or optionally substituted eyeloaliphatic, polycycloaliphatic, heterocycloaliphatic, or polyheterocycloaliphatic, C<sub>6</sub>-C<sub>12</sub> aromatic group or a C<sub>1</sub>-C<sub>9</sub> heteroaromatic group containing one, two, three, or four heteroatoms selected from oxygen, sulfur, or nitrogen;

Alk1 is an optionally substituted aliphatic or heteroaliphatic chain;

L<sup>1</sup> is a linker atom or group selected from the group consisting of -O-, -S-, -C(O)-, -C(O)O-, -C(S)-, -S(O)-, -S(O)<sub>2</sub>-, -N(R<sup>4</sup>)-, -OC(O)N(R<sup>4</sup>)-, -CSN(R<sup>4</sup>)-, --C(O)N(R<sup>4</sup>)-, -C(O)N(R<sup>4</sup>)-, -N(R<sup>4</sup>)CO-, -N(R<sup>4</sup>)C(O)O-, -N(R<sup>4</sup>)CS-, -S(O)N(R<sup>4</sup>)-, -S(O)<sub>2</sub> N(R<sup>4</sup>)-, -N(R<sup>4</sup>)S(O)-, -N(R<sup>4</sup>)S(O)<sub>2</sub>-, -N(R<sup>4</sup>)CON(R<sup>4</sup>)-, -N(R<sup>4</sup>)CSN(R<sup>4</sup>)-, -N(R<sup>4</sup>)SON(R<sup>4</sup>)- and -N(R<sup>4</sup>)SO<sub>2</sub> N(R<sup>4</sup>)-;

r and s, which may be the same or different, is each zero or an integer 1 provided that when r is zero, R<sup>1</sup>-is an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, or polyheterocycloaliphatic, aromatic or heteroaromatic group;

**PATENT** 

DOCKET NO.: CELL-0145 Application No.: 09/964,161 Office Action Dated: 04/23/2003

R<sup>a</sup> and R<sup>b</sup>, which may be the same or different, is each an atom or group -L<sup>2</sup>(CH<sub>2</sub>)<sub>p</sub>L<sup>3</sup>(R<sup>c</sup>)<sub>q</sub> in which L<sup>2</sup> and L<sup>3</sup> is each a covalent bond or a linker atom or group, p is
zero or the integer 1, q is an integer 1, 2 or 3 and R<sup>c</sup> is a hydrogen or halogen atom or a group
selected from straight or branched alkyl, OR<sup>d</sup> [where R<sup>d</sup> is a hydrogen atom or an optionally
substituted straight or branched alkyl group], -SR<sup>d</sup>, -NR<sup>d</sup>R<sup>c</sup>, [where R<sup>e</sup> is just defined for R<sup>d</sup>
and may be the same or different], -NO<sub>2</sub>, -CN, -CO<sub>2</sub>R<sup>d</sup>, -SO<sub>3</sub>H, SO<sub>2</sub>R<sup>d</sup>, -OCO<sub>2</sub>R<sup>d</sup>, -CONR<sup>d</sup>R<sup>c</sup>,
-OCONR<sup>d</sup>R<sup>c</sup>, -CSNR<sup>d</sup>R<sup>c</sup>, -COR<sup>d</sup>, -N(R<sup>d</sup>)COR<sup>c</sup>, -N(R<sup>d</sup>)CSR<sup>c</sup>, -SO<sub>2</sub>N(R<sup>d</sup>)(R<sup>e</sup>), -N(R<sup>d</sup>)SO<sub>2</sub>R<sup>e</sup>,
-N(R<sup>d</sup>)CONR<sup>e</sup>R<sup>f</sup>, [where R<sup>f</sup> is a hydrogen atom or an optionally substituted straight or
branched alkyl group], -N(R<sup>d</sup>)CSNR<sup>e</sup>R<sup>f</sup> or -N(R<sup>d</sup>)SO<sub>2</sub>NR<sup>e</sup>R<sup>f</sup>;

R<sup>d</sup>, R<sup>e</sup>, and R<sup>f</sup> are each, independently, a hydrogen atom or an optionally substituted straight or branched alkyl group;

Alk<sup>2</sup> is a straight or branched alkylene chain;

m is zero or an integer 1;

R<sup>2</sup> is a hydrogen atom or methyl group;

 $R^3$  and  $R^4$ , which may be the same or different, are each is a hydrogen atom or a straight or branched alkyl group;

Het is an optionally substituted <u>nine- to thirteen-membered fused-ring</u> heteroaromatic group;

and the salts, solvates, hydrates, and N-oxides thereof.

2-3. (canceled)

**PATENT** 

**DOCKET NO.:** CELL-0145 **Application No.:** 09/964,161 **Office Action Dated:** 04/23/2003

4. (currently amended) The A compound according to of Claim 1 wherein R is a -CO<sub>2</sub>H group.

5. (currently amended) The A compound according to of Claim 1 wherein Alk<sup>2</sup> is a --CH<sub>2</sub> -- chain and m is the an integer 1.

6. (currently amended) The A compound according to of Claim 1 wherein each of  $R^2$  and  $R^3$  is a hydrogen atom.

## 7. (canceled)

8 (currently amended) The A compound according to of Claim  $\underline{1}$  7 wherein  $R^1$  is an optionally substituted phenyl, pyridyl, or pyrimidinyl group.

9. (currently amended) The A compound according to of Claim 1 wherein –  $(Alk^1)_r(L^1)_s$  is a –CH<sub>2</sub>O-, -SO<sub>2</sub>NH-, -C(O)O-, or –CON(R<sup>4</sup>) group.

10. (currently amended) The A compound according to of Claim 9 wherein –  $(Alk^1)_r(L^1)_s$  is a –CONH group.

11 (currently amended) The A compound according to of Claim 1 which has the formula (1a):

**DOCKET NO.:** CELL-0145 **PATENT** 

Office Action Dated: 04/23/2003

Application No.: 09/964,161

wherein -W= is -CH= or -N=, R<sup>9</sup> and R<sup>10</sup>, which may be the same or different is each a  $-L^2(CH_2)_pL^3(R^c)_q$  atom or group as generally and particularly defined above, and  $Alk^4$ , r, L<sup>1</sup>, s, R<sup>a</sup>, R<sup>b</sup>, R and Het are as generally and particularly defined above, and the salts, solvates, hydrates and N-oxides thereof.

## 12-13. (canceled)

14. (currently amended) A pharmaceutical composition comprising a compound of according to Claim 1 together with one or more pharmaceutically acceptable carriers, excipients or diluents.